Close button
Enquiry IconContact Us
Logo
  • Choose License Type

China ulcerative colitis market, by Drug Therapy (5-Aminosalicylates, Monoclonal Antibodies, Steroids, Immunomodulators, and Antibiotics), by Route of Administration (Oral and Parenteral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), is estimated to be valued at US$ 185 million in 2021 and is expected to exhibit a CAGR of 2.9% over the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.

Key players operating in the market are focusing on receiving product approvals from regulatory authorities and this is expected to drive the market growth over the forecast period.

For instance, in October 2019, The Janssen Pharmaceutical Companies of Johnson & Johnson received the U.S. Food and Drug Administration’s (FDA) approval for STELARA (ustekinumab) to treat the adult patients with moderately to severely active ulcerative colitis. 

Moreover, in January 2020, AstraZeneca Plc, a research based biopharmaceutical company, announced to recover the global rights of Brazikumab from Allergan. Brazikumab is currently in a phase II b trial in ulcerative colitis (UC).

China Ulcerative Colitis Market – Impact of Coronavirus (COVID-19) Pandemic

COVID-19 outbreak was first reported on December 31, 2019, in Wuhan, China. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 259,502,031 cases and 5,183,003 deaths due to Coronavirus (COVID-19) were reported up till November 26, 2021, across the globe.

The COVID-19 pandemic has negatively affected several markets across the globe and is also expected to hamper the demand and supply in China ulcerative colitis market, owing to stringent regulatory standards during the COVID-19 outbreak.

For instance, as stated in the article published by National library of medicine, in July 2021, an inflammatory bowel disease such as ulcerative colitis is not a medical condition susceptible to acquire COVID-19, the only exception is patients treated with 5-aminosalicylates..

Browse 29 Market Data Tables and 16 Figures spread through 162 Pages and in-depth TOC on “Ulcerative Colitis Market”- China Forecast to 2028, by Drug Therapy (5-Aminosalicylates, Monoclonal Antibodies, Steroids, Immunomodulators, and Antibiotics), by Route of Administration (Oral and Parenteral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies),

To know the latest trends and insights prevalent in the Global Ulcerative Colitis Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/china-ulcerative-colitis-market-4862

Key players operating in the market are focusing on research and development to launch novel drug products in the market. For instance, in August 2021, Finch Therapeutics Group, Inc.,  works as a bio-pharmaceutical company, announced that Takeda Pharmaceutical Co. Ltd. had chosen to fast-track the development process of the FIN-524 ulcerative colitis development program. FIN-524 is a microbiome-targeting drug molecule for the treatment of ulcerative colitis.

Key Takeaways of the China Ulcerative Colitis Market:

  • The China ulcerative colitis market is expected to exhibit a CAGR of 2.9% over the forecast period, owing to increase in number drug products in the pipeline. For instance, in February 2021, Arena Pharmaceutical Inc., a clinical stage pharmaceutical company announced about the completion of enrolment of the phase III ELEVATE UC 52 trial for evaluating the efficacy and safety of Etrasimod. It is an oral sphingosine 1-phosphate (S1P) receptor modulator in moderate to severe ulcerative colitis.
  • Among drug therapy, 5-Aminosalicylates segment is expected to account for largest market share during the forecast period, owing to increasing drug launches. For instance, in May 2019, Teva Pharmaceutical Industries Ltd., one of the leaders in pharmaceutical industries launched generic version of delayed release capsule Delzicol (mesalamine). It is indicated for mild to moderate ulcerative colitis and for maintenance to reduce signs and symptoms of ulcerative colitis in adults.
  • Key players operating in the China ulcerative colitis market include AbbVie Inc., Celltrion Healthcare, Johnson & Johnson Services, Inc., F. Hoffmann-La Roche AG, Arena Pharmaceuticals, Takeda Pharmaceuticals Company Ltd., Finch Therapeutics Group, Inc., GlaxoSmithKline Plc., Eli Lilly and Company, AstraZeneca, Pfizer Inc., Amgen, BRISTOL-MYERS SQUIBB, Athos Therapeutics, Inc., Teva Pharmaceutical Industries Ltd., and Tillotts Pharma AG.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly subscribe for our latest news & articles.